Fluoxetine (Prozac) is the only SSRI consistently linked to weight loss, with studies showing an average short-term loss of up to 3.3 kg (about 7 pounds) in obese patients. But that effect is temporary. Most SSRIs, including fluoxetine, lead to weight gain over the long term, which makes the full picture more complicated than the search might suggest.
Fluoxetine Is the Standout
Among all SSRIs, fluoxetine has the strongest evidence for causing weight loss. In clinical trials for depression, patients on fluoxetine lost a small but measurable amount of weight in the first weeks to months of treatment. In studies of obese patients specifically, the average loss was up to 7 pounds in the short term.
Fluoxetine is also the only SSRI approved by the FDA to treat binge-eating and purging behaviors in bulimia nervosa, where the effective dose (60 mg daily) is higher than what’s typically prescribed for depression. In a 16-week trial for bulimia, patients on 60 mg lost about 1 pound on average while those on placebo gained a small amount. About 8% of patients on fluoxetine reported decreased appetite, compared to 4% on placebo. The weight loss effect isn’t dramatic, but it’s the clearest signal of any SSRI pushing weight downward rather than up.
What About Sertraline and Paroxetine?
Sertraline (Zoloft) and paroxetine (Paxil) show a more mixed pattern. FDA adverse event reports include both weight gain and weight loss among patients taking these medications, meaning individual responses vary widely. However, the overall trend for both leans toward gain rather than loss.
A large observational study comparing sertraline to other antidepressants found that sertraline was associated with about half a pound of weight gain at six months and 3.2 pounds at two years. That makes it relatively weight-neutral compared to some antidepressants, but it’s not a weight loss medication by any stretch. Paroxetine, meanwhile, is generally considered one of the SSRIs most likely to cause weight gain.
Why SSRIs Affect Appetite at All
SSRIs work by increasing serotonin levels in the brain, and serotonin plays a direct role in regulating hunger and fullness. The appetite-suppressing effects of SSRIs appear to involve a complex interaction with specific serotonin receptors. Animal research has shown that fluvoxamine (Luvox), another SSRI, can suppress appetite when combined with the blockade of a particular serotonin receptor subtype, though neither the drug nor the receptor blockade has that effect alone.
This complexity helps explain why appetite changes on SSRIs are so unpredictable from person to person. The same drug can reduce appetite in one patient and increase it in another, depending on individual brain chemistry, genetics, and baseline metabolic factors.
The Weight Loss Doesn’t Last
This is the most important thing to understand: the weight loss seen with fluoxetine and other SSRIs is a short-term phenomenon. A one-year trial of fluoxetine at 20 mg daily tracked exactly how this plays out. During the first phase of treatment, patients lost a small but statistically significant amount of weight (about 0.35 kg). Then the trajectory reversed. By 26 weeks, patients had gained an average of 1.1 kg. By 38 weeks, 2.2 kg. By 50 weeks, 3.1 kg (nearly 7 pounds).
This pattern of initial weight loss followed by gradual gain over the first year is a common clinical finding with SSRIs as a class. It wasn’t captured in the original short-term drug trials, which is partly why many people are surprised when the scale starts moving in the wrong direction after a few months. The early appetite suppression fades, and longer-term metabolic and behavioral effects take over.
Choosing an Antidepressant With Weight in Mind
If weight is a significant concern, SSRIs as a group are not the best option for avoiding gain. A 2025 review in The Lancet Psychiatry on treating depression in people with obesity noted that no formal clinical guidelines exist for this specific patient group, but recommended avoiding mirtazapine and tricyclic antidepressants, which carry the highest risk of weight gain. The review favored bupropion (Wellbutrin), which is not an SSRI but works on different brain chemicals and is one of the few antidepressants consistently associated with weight loss or weight neutrality over time.
Among SSRIs specifically, fluoxetine carries the lowest risk of long-term weight gain, but “lowest risk” is not the same as “causes weight loss.” If you’re taking an SSRI and noticing appetite changes in either direction, that’s a normal variation in how these drugs affect different people. The decision about which antidepressant to take involves balancing many factors, and weight effects are just one piece of a larger conversation about what works for your depression or anxiety.